anti-thyroid drugs-related myopathy: is carbimazole the real culprit?

نویسندگان

chiu chi tsang department of medicine, alice ho miu ling nethersole hospital, hong kong, china; department of medicine, alice ho miu ling nethersole hospital, hong kong, china. tel: +852-26892000, fax: +852-26892472

wai shan hui department of medicine, alice ho miu ling nethersole hospital, hong kong, china

kwun man lo department of medicine, alice ho miu ling nethersole hospital, hong kong, china

jonas hon ming yeung department of medicine, alice ho miu ling nethersole hospital, hong kong, china

چکیده

case presentation a 28-year old chinese female was treated with carbimazole (cmz) for graves’ disease with hyperthyroidism. two weeks later, she developed myalgia and proximal muscle weakness. investigations showed evidence of myopathy. cmz was stopped and rapid improvement of clinical condition and biochemical parameters ensued. conclusions rapid decrement of thyroid hormone level is recognized as an important association for anti-thyroid drugs (atds)-related myopathy; however, the drug effects on muscle tissue cannot be excluded. further elucidation of pathophysiology and identification of risk factors are needed. after commencing atds, early recognition of this rare condition and close monitoring are the essence of management. different treatment strategies: dose reduction of atds, switching to alternative atds, with or without addition of thyroid hormone supplement can be applied depending on clinical situation. introduction anti-thyroid drugs (atds)-related myopathy is rarely reported in literature, but once developed, it can cause significant morbidity to patient.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Anti-Thyroid Drugs-Related Myopathy: Is Carbimazole the Real Culprit?

INTRODUCTION Anti-thyroid drugs (ATDs)-related myopathy is rarely reported in literature, but once developed, it can cause significant morbidity to patient. CASE PRESENTATION A 28-year old Chinese female was treated with carbimazole (CMZ) for Graves' disease with hyperthyroidism. Two weeks later, she developed myalgia and proximal muscle weakness. Investigations showed evidence of myopathy. C...

متن کامل

Thyroid function tests during carbimazole therapy.

Changes in plasma thyroxine (T4), triiodothyronine (T3), free thyroxine index (FT4I) and thyroid stimulating hormone were studied in 100 patients with Graves' disease treated with carbimazole. During therapy plasma T3 concentrations were disproportionately high compared to those of T4, the T4 : T3 ratio was low, and many patients were clinically euthyroid with a normal plasma T3 but low T4 conc...

متن کامل

Where is the culprit?

Address for Correspondence: Dr. Şükrü Akyüz, Tıbbıye Cad. No: 23, Siyami Ersek Göğüs ve Kalp Damar Cerrahisi Eğitim ve Araştırma Hastanesi, İstanbul-Türkiye Phone: +90 532 340 74 72 Fax: +90 216 444 52 57 E-mail: [email protected] Available Online Date: 09.04.2015 ©Copyright 2015 by Turkish Society of Cardiology Available online at www.anatoljcardiol.com DOI:10.5152/akd.2015.6241 Diagnosti...

متن کامل

Propylthiouracil, and methimazole, and carbimazole-related hepatotoxicity.

INTRODUCTION Propylthiouracil (PTU) has been used for the treatment of hyperthyroidism since the 1940s, but over the years reports of significant hepatotoxicity have come forth, particularly in children. This led to a black box warning being issued by the US FDA in 2009, followed by a similar warning by the European Medicines Agency and the United Kingdom Medicines and Healthcare Regulatory Age...

متن کامل

منابع من

با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید


عنوان ژورنال:
international journal of endocrinology and metabolism

جلد ۱۳، شماره ۱، صفحات ۰-۰

میزبانی شده توسط پلتفرم ابری doprax.com

copyright © 2015-2023